Podcasts about Prostate cancer

There is a new treatment option available now that can precisely target prostate lesions with electrical pulses, while helping preserve sexual function and urinary control. Whether you or a loved one has prostate disease, or you are a urologist considering this technology for your practice, you will not want to miss today's discussion on this innovative new option. September is Prostate Cancer Awareness Month, so we have a special episode today to kick it off. We are excited to welcome the distinguished urologist, Dr. Spencer Krane, to the Prostate Health Podcast. Dr. Krane is the Chief of Urology at the US Department of Veterans Affairs in New Orleans, Louisiana. He specializes in personalized medicine for patients with urologic malignancies, aiming to use new biomarkers, genomic classifications, epigenetic signatures, and advanced imaging modalities, including MRI-guided prostate biopsies, to offer his patients individualized care that improves cancer outcomes while minimizing therapy side effects. Dr. Krane has published extensively in urologic journals, and his work was selected to provide guidelines for urologic care. He has 50 peer-reviewed articles in national and international journals and has presented his work internationally, from Chile and Rome to Taiwan, as well as across the United States. We are excited to welcome him today to share his experience with the innovative new NanoKnife system as a treatment option for men with prostate tumors.  It is exciting to see ongoing innovation in the technology we have available for men with prostate tumors. For the appropriate candidates, this minimally invasive option offers precise targeting of the lesion while helping preserve both sexual function and urinary control.  Pertinent disclosure for today's episode – Dr. Krane is a paid consultant for AngioDynamics, Inc., which manufactures and sells the NanoKnife System. The views, information, and opinions expressed in this podcast are solely those of Dr. Krane, and does not necessarily represent those of AngioDynamics, Inc., its affiliates, or subsidiaries.  Show Highlights: Dr. Krane reviews the concept of targeted focal therapy and explains what  the NanoKnife system is Who is an ideal candidate for irreversible electroporation with the NanoKnife system? The advantages and features of the NanoKnife system   Does prostate size or shape limit the candidacy for IRE with the NanoKnife system? Would prostate anatomies on the MRI or biopsy exclude a patient from NanoKnife therapy? Dr. Krane explains how long it takes to resolve the initial decrease in sexual ability after NanoKnife therapy.   Why many patients experience improved urinary function in the long term after having NanoKnife therapy Dr. Krane clarifies the time it takes to resolve the initial decrease in sexual ability after being treated with NanoKnife therapy.   Links:  Follow Dr. Pohlman on Twitter and Instagram - @gpohlmanmd.  Get your free What To Expect Guide (or find the link on our podcast website)   Join our Facebook group  Follow Dr. Pohlman on X and Instagram  Sign up for the Prostate Health Academy   You can access Dr. Pohlman's free mini-webinar, where he discusses his top three tips to promote men's prostate health, longevity, and quality of life here.  

At Sarasota Memorial, the multi-disciplinary cancer care team provides prostate screening and diagnostic biopsy services, along with comprehensive care. Kunal Saigal, MD, Medical Director of Radiation Oncology at the Brian D. Jellison Cancer Institute, discusses the latest advancements in prostate cancer treatment, including the use of Pluvicto.You can also watch the video recording on our Vimeo channel here.For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

This week on Health Matters, Courtney talks with urologic oncologist Dr. Michael Feuerstein of Columbia and NewYork-Presbyterian The One, a new center for advanced care in Westchester, to discuss the importance of screening for prostate cancer. Dr. Feuerstein explains how blood tests work to detect prostate cancer, explores the latest advancements in treatment, and debunks common myths and misunderstandings about prostate health. ___Dr. Michael Feuerstein, MD, MPH, is the chief of urology at NewYork-Presbyterian Westchester and assistant professor in the Department of Urology at Columbia University Vagelos College of Physicians and Surgeons. Dr. Feuerstein is a board-certified urologist with over ten years of experience, specializing in minimally-invasive surgery for prostate, kidney, and bladder cancer. He received his medical degree and completed his urology residency training at Albany Medical Center. He completed a two-year fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center and received a master's degree in public health at the Columbia Mailman School of Public Health. Dr. Feuerstein's research focuses on improving quality of care and quality of life for patients diagnosed with urologic cancers. Dr. Feuerstein provides care at NewYork-Presbyterian The One, a state-of-the-art center for advanced care with doctors from Columbia in Westchester. The facility offers adult and pediatric care spanning more than 90 specialties and subspecialties, so patients can find the care they and their families need in one convenient location.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

Welcome to another powerful episode of Navigating Cancer TOGETHER, hosted by Talaya Dendy.In this episode, we shine a spotlight on prostate cancer awareness, the critical issue of health disparities, and the vital importance of open conversations within the Black and African American community. Talaya is joined by a remarkable guest, Christopher Shaddock, a veteran and prostate cancer survivor who shares his powerful personal journey. From his unique experience living in Iceland to his candid discussion about the emotional and physical impacts of his diagnosis, Christopher's story is one of determination, advocacy, and hope.This episode is a must-listen for men, caregivers, and advocates who want to understand the unique challenges of a prostate cancer diagnosis and the power of sharing one's story and creating a domino effect.✨Highlights from the show:3:12 Christopher shares his unique experience living in Iceland9:49 Christopher's prostate cancer diagnosis story10:55 The emotional impact of diagnosis and treatment16:39 Side effects of prostate cancer treatment: what men should know24:34 Addressing health disparities and barriers for African American men30:25 The importance of support groups and advocacy32:23 The “domino effect” of sharing your story and inspiring othersTranscript: https://bit.ly/podscript171ResourcesThe Silent Killer - https://www.silentkillerdoc.comThe Ties That Bind - https://www.bluechildentertainment.com/the-ties-that-bind-crowdfundingZero Prostate Cancer - https://zerocancer.org/black-menRespond Study - https://www.respondstudy.org

What if prostate cancer treatment weren't months of daily radiation—but five ultra-precise sessions guided in real time by MRI? Today, Dr. Michael J. Zelefsky (Professor of Radiation Oncology, NYU Grossman School of Medicine) explains how MRI-LINAC and adaptive planning are redefining accuracy, reducing side effects, and personalizing care. A pioneer behind IMRT and image-guided radiotherapy, Dr. Zelefsky breaks down SBRT vs. IMRT, protons vs. photons, HDR brachytherapy, when to add hormone therapy, and how genomics + AI are shaping what's next.In this conversation, Dr. Zelefsky charts the evolution from long-course radiation to short-course SBRT with outcomes comparable to 7–9 week regimens—thanks to precision imaging and planning. He clarifies where IMRT ends and SBRT begins, why protons haven't shown superiority over photons in prostate cancer, and where HDR brachytherapy (Ir-192) shines—especially as a boost in higher-risk disease. We dig into dose equivalence (why 5×8 Gy can match ~80–90 Gy long-course), risk-based treatment + ADT duration, and how Decipher/Artera scores can refine decisions. Most exciting: MRI-LINAC with continuous motion monitoring keeps the prostate in a virtual “bullseye,” enabling whole-gland treatment with focal boosts today—and potentially true focal therapy tomorrow as biologic imaging and AI mature.Time-Stamped Highlights00:00 – Welcome 02:00 – Why Dr. Zelefsky's work is so respected; career arc and impact04:00 – What changed: CT/MRI planning → 3D-CRT → IMRT → SBRT12:45 – IMRT vs. SBRT: definitions, session counts, who gets what19:10 – Energy sources overview: photons, protons, brachytherapy20:30 – Protons vs. photons: evidence, indications, cost, access24:00 – HDR brachytherapy (Ir-192) as a temporary “in-and-out” boost28:00 – Dose logic: why 5×8 Gy (~40 Gy) ≈ long-course 80–90 Gy29:30 – Risk groups (low/intermediate/high) and when ADT is crucial33:00 – ADT durations (6–36 months): what trials actually showed37:00 – Genomics (Decipher/Artera): resolving risk discrepancies39:00 – What MRI-LINAC adds: real-time adaptive planning43:00 – Continuous Motion Monitoring (CMM): beam stops if target moves47:00 – Treat whole gland + boost the DIL (FLAME study approach)49:00 – Toward focal therapy with better biologic imaging + AI54:00 – How to choose: values, side-effects, lifestyle, comorbidities01:01:00 – Final guidance: don't be overwhelmed—multiple good option

In this episode, we will talk with Dr. Okey Enyia, a health policy executive, government relations leader, and scholar-activist whose work sits at the intersection of public health, advocacy, and equity. He is the author of his second forthcoming book The John Henry Health Equity Playbook: A Four-Year Policy Agenda for Black Men, which lays out a bold roadmap to improve health outcomes, strengthen families, and transform systems of care.

In this program: ALC feature about Prostate Cancer, Oliver Slewa talking about privacy awareness and in Australia explained: How to deal when confronted with wildlife in Australia

Africa Melane speaks to CEO Prostate Cancer Foundation, about their latest Suit Up September campaign. To help raise awareness for prostate cancer Early Breakfast with Africa Melane is 702’s and CapeTalk’s early morning talk show. Experienced broadcaster Africa Melane brings you the early morning news, sports, business, and interviews politicians and analysts to help make sense of the world. He also enjoys chatting to guests in the lifestyle sphere and the Arts. All the interviews are podcasted for you to catch-up and listen. Thank you for listening to this podcast from Early Breakfast with Africa Melane For more about the show click https://buff.ly/XHry7eQ and find all the catch-up podcasts here https://buff.ly/XJ10LBU Listen live on weekdays between 04:00 and 06:00 (SA Time) to the Early Breakfast with Africa Melane broadcast on 702 https://buff.ly/gk3y0Kj and CapeTalk https://buff.ly/NnFM3N Subscribe to the 702 and CapeTalk daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702 CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

Prostate cancer may sound daunting, but the reality around its mortality risk can be surprisingly different from what most believe. In this episode, Dr. Stephen Petteruti takes a bold stance against the one-size-fits-all approach to prostate cancer treatment. Referencing pivotal studies like the Pivot and ProtecT trials, he shows that conventional treatments such as prostate removal, radiation, and biopsies often fail to improve longevity and in some cases, may cause more harm than good. The real threats to life? Heart disease, infections, and even treatment-induced complications.Dr. Stephen invites listeners to question the status quo and broaden their perspective. He offers strategic alternatives, including lifestyle changes and a focus on overall health, rather than just the prostate.Tune into the full episode of The Surprising Truth About Prostate Cancer and Mortality.Enjoy the podcast? Subscribe and leave a 5-star review. Dr. Stephen Petteruti is a leading Functional Medicine Physician dedicated to enhancing vitality by addressing health at a cellular level. Combining the best of conventional medicine with advancements in cellular biology, he offers a patient-centered approach through his practice, Intellectual Medicine 120. A seasoned speaker and educator, he has lectured at prestigious conferences like A4M and ACAM, sharing his expertise on anti-aging. His innovative methods include concierge medicine and non-invasive anti-aging treatments, empowering patients to live longer, healthier lives.Website: www.intellectualmedicine.com Website: https://www.theprostateprotocol.com/ YouTube: https://www.youtube.com/@intellectualmedicine LinkedIn: https://www.linkedin.com/in/drstephenpetteruti/ Instagram: instagram.com/intellectualmedine Consultation: https://www.theprostateprotocol.com/book-a-consultation Store: https://www.theprostateprotocol.com/store Community: https://www.theprostateprotocol.com/products/communities/v2/fightcancerlikeaman/home    Disclaimer:  The content presented in this video reflects the opinions and clinical experience of Dr. Stephen Petteruti and is intended for informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional diagnosis, treatment, or guidance from your personal healthcare provider. Always consult your physician or qualified healthcare professional before making any changes to your health regimen or treatment plan.Produced by https://www.BroadcastYourAuthority.com 

September is Prostate Cancer Awareness month, with the disease now the most common cause of death from cancer for men in Australia. Advocacy groups are pushing for greater awareness and regular testing for all men in the country, including those from a multicultural background.

Southern Remedy Healthy and Fit is hosted by Josie Bidwell, Professor of Preventive Medicine and Nurse Practitioner at UMMC. If you have a question for Josie, you can email fit@mpbonline.org. It this episode, Josie is joined by Dr. Justin Turner, community health office for the Cancer Center and Research Institute at UMMC to discuss prostate cancer. If you enjoy listening to this podcast, please consider contributing to MPB. https://donate.mpbfoundation.org/mspb/podcast. Hosted on Acast. See acast.com/privacy for more information.

September is Prostate Cancer Awareness month, with the disease now the most common cause of death from cancer for men in Australia. Advocacy groups are pushing for greater awareness and regular testing for all men in the country, including those from a multicultural background.

Prostate cancer is the most common cancer diagnosed in men and the five year survival rate is 97%.

One of our most popular podcasts ever was the one called "Gleason 6 prostate cancer | Why we should rename it (and why we can't)!", posted in December 2022, and featuring Urologists Scott Eggener (Chicago) and Matt Cooperberg), plus Pathologist Eva Comperat (Paris/Vienna). In fact, we still get so many hits on this and active comments on our YouTube site that we thought we better re-visit it!!! Is Gleason 6/Grade Group 1 really cancer at all?? Can't we just re-name it and declare it not-a-cancer??! Scott and Matt re-join GU Cast today to update us on the campaign! With usual hosts Renu Eapen and Declan MurphyEven better on our YouTube channelLinks:JNCI paper October 2024 Our Dec 2022 podcast on renaming Gleason 6 

learned three things from my battle with prostate cancer that apply directly to business and leadership: Consistency. Every day for 38 days, I showed up for treatment. The process worked because of steady, disciplined action—not intensity, but consistency. In business, the same truth applies: sustained effort beats occasional bursts. Alignment. On the treatment table, alignment had to be precise. If I was off by even a fraction, the laser would miss the target. In business, alignment is just as critical—between strategy and execution, vision and people. Small misalignments compound into major misses. Culture. From beginning to end, the staff created an environment of care, respect, and professionalism. Their culture made a difficult process not only bearable but supportive. In business, culture defines the experience—both for your team and your customers. Consistency, alignment, and culture—whether in health or in business—are not optional. They are the difference between surviving and thriving.

This episode offers a detailed clinical update on the early detection and diagnosis of prostate cancer, tailored for the primary care setting. Dr Bunmi Olajide, a GP with a special interest in cancer services and a Prostate Cancer UK Clinical Champion, presents an evidence-based review of the significant changes to the diagnostic pathway. The discussion highlights how the integration of multi-parametric MRI has led to a 79% reduction in the risk of harm and 90% fewer cases of post-procedure sepsis.Dr Olajide provides a nuanced analysis of risk stratification, addressing the significant health inequalities that result in a doubled risk for Black men. The discussion covers the clinical application of NICE guidelines, the interpretation of PSA results in the context of confounding factors, and the diminishing role of the DRE as a screening tool. This is an essential briefing for clinicians seeking to align their practice with the latest evidence in prostate cancer management.Key topics discussed in this episode:An overview of the current epidemiology of prostate cancer in the UK.A review of key risk factors, including the 1-in-4 lifetime risk for Black men.Practical application of the NICE NG12 guidelines and age-specific PSA thresholds.The Prostate Cancer Risk Management Programme for managing asymptomatic men.The evolution of the diagnostic pathway and the role of multi-parametric MRI.A critical appraisal of the digital rectal examination (DRE) in screening for prostate cancer.An introduction to the large-scale Transform screening trial, which is examining approaches beyond PSA testing.Professional resources and educational opportunities for healthcare professionals.

Dr Bill Nelson and Dr Sam Denmeade discuss the growing array of treatments for patients with prostate cancer available at the Johns Hopkins Kimmel Cancer Center.

NBC News Senior Business Analyst Stephanie Ruhle shares tips on bouncing back from summer spending. Also, an exclusive interview with Montell Jordan on Prostate Cancer Awareness Month and his journey following his diagnosis last year. Plus, bestselling author Xochitl Gonzalez shares the best new book releases this month. 

Two-time Busch Series champion Randy LaJoie was diagnosed with prostate cancer in July, and he agreed to sit down with host Rick Houston last week to tell his story. Following the interview with Randy, Rick and co-host Steve Waid respond with some thoughts of their own and then close the episode with a conversation with Deb Williams, former editor of Winston Cup Scene and the recently announced 2026 recipient of the Squier-Hall Award for NASCAR Media Excellence. NOTE: This show is not associated in any way with American City Business Journals, owner of the Scene brand. Be sure to check out the latest and greatest stories from the world of NASCAR at dailydownforce.com! Interested in The Scene Vault Podcast T-shirts? Check out thescenevault.com and click on SHOP to see what we have available! Please consider supporting this show via: patreon.com/thescenevaultpodcast paypal.me/thescenevaultpodcast venmo.com/thescenevaultpodcast Learn more about your ad choices. Visit megaphone.fm/adchoices

On today's episode of Integrative Cancer Solutions host Dr. Michael Karlfeldt is joined by guest Gordon McMurray. Gordon's journey with prostate cancer began with a family history of the disease and early detection through a PSA test, which led to his diagnosis in September 2022. He describes the initial shock and the process of coming to terms with the diagnosis, emphasizing the importance of early testing and awareness, especially for those with a family predisposition. Gordon's background in risk management and compliance helped him navigate the complex landscape of treatment options and make informed decisions about his care. When considering treatment, Gordon explored several options, including surgery, radiotherapy, HIFU (High-Intensity Focused Ultrasound), and brachytherapy. Ultimately, he chose surgery, performed by an experienced professor, after weighing the pros and cons of each method and considering regional availability—HIFU was not accessible in Scotland, and brachytherapy was only a marginal possibility. He highlights the challenges of accessing consistent treatment across different regions and the importance of understanding the implications of each option, including the potential side effects and long-term outcomes. The impact of treatment on Gordon's daily life was significant. He experienced side effects such as frequent urination, fatigue, and a brief episode of back pain related to his prostate condition. Gordon discusses the importance of understanding PSA readings, the limitations of the test, and the need for informed consent throughout the treatment process. He also shares practical advice on managing fatigue, such as staying hydrated and incorporating exercise, and stresses the importance of making lifestyle adjustments to cope with ongoing side effects. Emotionally and psychologically, Gordon's experience was challenging, involving periods of anxiety and depression. He worked with a psychology student to better understand the psychological impact of prostate cancer recovery and underscores the need for emotional support for both patients and their partners. Gordon points out the lack of psychosexual treatment options in the UK and the value of external support services like Prostate Cancer UK and Macmillan, which provide crucial resources for those navigating the recovery process. In reflecting on his journey, Gordon expresses gratitude for the support he received and the opportunity to share his story. He advises others to stay informed, make timely decisions, and seek out support networks, including peer groups and online communities. Gordon's experience underscores the importance of early detection, informed decision-making, and the availability of comprehensive support resources for prostate cancer patients and their families, offering hope and guidance to others facing similar challenges.Gordon McMurray shared his personal journey with prostate cancer, emphasizing the importance of early detection through PSA testing and family history awareness.He discussed the challenges of choosing between treatment options like surgery, HIFU, and brachytherapy, ultimately opting for surgery due to regional availability.Gordon described the significant side effects of treatment, including urinary issues, fatigue, and the need for lifestyle adjustments.He highlighted the emotional and psychological impact of prostate cancer, stressing the importance of support for both patients and their partners.Gordon advised others to stay informed, seek support networks, and make timely, well-considered decisions about their health and treatment options.----Grab my book A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health Threat - https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering Cancerhttps://store.thekarlfeldtcenter.com/products/unleashing-10x-power-Price: $24.99-100% Off Discount Code: CANCERPODCAST1Healing Within: Unraveling the Emotional Roots of Cancerhttps://store.thekarlfeldtcenter.com/products/healing-within-Price: $24.99-100% Off Discount Code: CANCERPODCAST2----Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

On this episode host Jonathan Chance talks with renowned Uro-oncologist Dr. Grgur Miric about whole body health to fight prostate cancer & other diseases.  On this episode Jonathan and Dr. Miric talk about:·       What the word cancer means. ·       The risk factors for cancer and prostate cancer.·       New technology that shows promise for cancer prevention and early detection.·       How exercise can help treat prostate cancer.·       The importance of a heart healthy diet.·       Why early detection is key when it comes to prostate cancer and other diseases.Prostate Cancer Aware is grateful to the Jevan and Ruzanna Chimayan Foundation for their generous donation, which will help fuel our podcast to raise critical awareness about prostate cancer and the PSA test around the world.Prostate Cancer Aware is a copyrighted production. No content maybe rebroadcast or reproduced without the expressed written consent of the Friedman Sidrow Foundation. For more information about prostate cancer, the PSA test, men's health and Jonathan's inspiring new book Unaware, which is about his battle with prostate cancer. Visit our website at: https://www.iknowmypsa.org Email us at: https://www.iknowmypsa.org/contactus/ Follow Prostate Cancer Aware on social media at: Facebook - https://www.facebook.com/iknowmypsa Twitter - https://twitter.com/iknowmypsa or @iknowmypsa Thank you for listening! Remember, Stay Aware and Stay Healthy.™

In today's episode, supported by Sumitomo, we spoke with Tanya B. Dorff, MD, about the use of androgen deprivation therapy (ADT) in patients with prostate cancer. Dr Dorff is section chief of the Genitourinary Disease Program, as well as a professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California. In our conversation, Dr Dorff discussed the role of ADT in prostate cancer management, highlighting where this class of agents fits into National Comprehensive Cancer Network guidelines and how this class has evolved with the development of LHRH antagonists and agonists. She explained how the observational OPTYX study (NCT05467176), a registry of relugolix (Orgovyx) use, aims to address safety and efficacy in combination with androgen receptor pathway inhibitors in patients with advanced prostate cancer. She also noted how early data from OPTYX presented at the 2025 ASCO Annual Meeting showed relugolix's use in localized and metastatic settings. Dorff also talked through relugolix's safety profile, particularly regarding cardiovascular risk, as well as the quality-of-life effects associated with ADT. She also addressed strategies to mitigate financial toxicity, along with the potential for future ADT-sparing treatments.

September is Prostate Cancer Awareness month, my co-host is Prostate Cancer advacate Elizabeth Jordan, She and her husband Daniel wrote the must read book "Empower your Journey:A prostate cancer guidebook -you can get on Amazon.com,  She has the podcast - Why so serious  https://www.spreaker.com/show/6686754/episodes/feed  On Sept 20, they will host a worldwide bell ringing for postate cancer on YouTube @lizjordan2649  we also talked,National Pierce your ears day. Entertainment from 1984. Great fire of London 1666. America goes from Julian to Gregarian calender. Japan formally surrendered ending WW2. Todays birthdays - Lili'uakalani, Rick Lewis, Mary Jo Catlett, Billy Preston, Mark Harmon, Keanu Reeves, Salma Hayek Pinault. JRR Tolkien died.Intro - God did good - Dianna Corcoran     https://www.diannacorcoran.com/What's love got to do with it - Tina TurnerTennesse homesick blues - Dolly PartonBirthdays - In da club - 50 Cent http://50cent.com/Aloha Oe - Tia CarrereGet a job - The SilhouettesNothing from nothing - Billy PrestonExit - Drink to much -  Mark McKinney      https://www.markmckinney.com/History and Factoids webpagecountryundergroundradio.com

SYLVIE BELJANSKI, author, WINNING THE WAR ON CANCER,  discusses the herbal formulas used to heal French President Francois Mitterrand of advanced Prostate Cancer during his second term of office   WOUTER BIJDENIJK, author, PLANT POWER Heal yourself with Medicinal Mushrooms, Roots, Flowers and herbs   BARBARA MINTON, PhD  Psychologist, musician and neuroscientist whose innovative work bridges the powerful intersection of music, neuroscience and emotional healing.  Barbara has a brand new album CALM THE STORM with world class musician Peppino D'Agostino  

In this episode, we welcome Dr. Michaël Baboudjian from Marseille, France, to discuss the topic of Active Surveillance for prostate cancer.Discover:The principles of active surveillanceThe key elements of an effective surveillance strategyThe collaboration between radiologists and urologistsThe criteria for selecting patients eligible for active surveillanceFinding the right balance between under- and overtreatmentHosted by Ausha. See ausha.co/privacy-policy for more information.

HIFU (high-intensity focused ultrasound) is one of the most talked-about focal therapies in prostate cancer—but who is it really right for? In this conversation, Dr. Matthew Cooperberg (UCSF)—a leading voice in urology, epidemiology, and integrative prostate cancer care—breaks down patient selection vs. energy modality, how modern imaging (MRI, fusion, RSI) drives precision, what genomics (e.g., Decipher) can and can't tell us, and how salvage options compare after focal therapy vs. radiation. We also tackle lifestyle factors, trial design, and why midlife PSA screening (ideally

The Smart 7 is an award winning daily podcast, in association with METRO that gives you everything you need to know in 7 minutes, at 7am, 7 days a week...With over 18 million downloads and consistently charting, including as No. 1 News Podcast on Spotify, we're a trusted source for people every day and the Sunday 7 won a Gold Award as “Best Conversation Starter” in the International Signal Podcast Awards If you're enjoying it, please follow, share, or even post a review, it all helps...Today's episode includes the following guests:Guests Al Gore - Former US Vice President and Climate Change activistDesmond Alugnoa - CEO of the GAYO recycling project in GhanaNinna Granucci - Co- Founder of Ferment'UpTasha and Natalie - Earthshot Youth Leaders Will Guyatt - The Smart 7's Tech Guru Amy Rylance - Assistant Director of Health Improvement at Prostate Cancer UK Dermot Murnaghan - Former Sky News Anchor Luke Ablitt - Potato farmer in Peterborough David Barton - Beef farmer in the Cotswold'sElspeth McDonald - CEO of the Scottish Fisherman's Federation Professor Bassel Watter - Consultant Obstetrician and Gynecologist, and Associate Professor of Reproductive Medicine at Anglia Ruskin University Doctor Ippokratis Sarris - Director at King's Fertility, Kings College London Paul Leader - Ecologist and Ornithologist Contact us over @TheSmart7pod or visit www.thesmart7.com or find out more at www.metro.co.uk Presented by Ciara Revins, written by Liam Thompson, researched by Lucie Lewis and produced by Daft Doris. Hosted on Acast. See acast.com/privacy for more information.

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

Urologic oncologist Dr. Peter Carroll presents the latest research on active surveillance as a preferred approach for managing low-risk prostate cancer and selected cases of intermediate-risk disease. Drawing from two decades of UCSF data, he explains how long-term outcomes support the safety and effectiveness of delaying treatment for carefully monitored patients. Carroll emphasizes that surveillance decisions should be guided by MRI imaging, PSA density, cancer volume, histologic subtype, and genomic testing. He notes that while many men experience gradual changes over time, only a small percentage require immediate treatment. Carroll also discusses innovations such as AI-assisted pathology and risk profiling to reduce unnecessary procedures. His data-driven approach offers patients a personalized path that preserves quality of life without compromising outcomes. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40801]

In this episode, Dr. Kian Asanad, a urologist Henry Mayo Newhall Hospital and Keck Medicine of USC, joins us to talk about one of the most common cancers affecting men: prostate cancer.Dr. Asanad breaks down everything you need to know—from how men get prostate cancer and who's at risk, to the latest screening tools, diagnostic methods, and treatment options. He also discusses when men should start screening and what side effects patients can expect from different treatments. Whether you're looking to be proactive about your health or support a loved one, this episode offers clear, expert insight into a critical topic.

Send us a textWhat if AI could predict cancer outcomes better than traditional methods—and at a fraction of the cost? In this episode, I explore how multimodal AI is reshaping lung and prostate cancer predictions and why integration challenges still stand in the way.Episode Highlights with Timestamps:[00:02:57] Agentic AI in toxicologic pathology – what it is and how it could orchestrate workflows.[00:05:40] Grandium desktop scanners – making histology studies more accessible and efficient.[00:08:03] Clover framework – a cost-effective multimodal model combining vision + language for pathology.[00:13:40] NSCLC study (Beijing Chest Hospital) – AI predicts progression-free and overall survival with high accuracy.[00:17:58] Prostate cancer prognostic model (Cleveland Clinic & US partners) – validating AI-enabled Pathomic PRA test.[00:23:35] Thyroid neoplasm classification – challenges for AI in distinguishing overlapping histopathological features.[00:34:49] Real-world Belgium case study – AI integration into prostate biopsy workflow reduced IHC testing and turnaround time.[00:41:03] Lessons learned – adoption hurdles, system integration, and why change management is essential for successful digital transformation.Resources from this EpisodeWorld Tumor Registry – A global open-access repository for histopathology images: World Tumor RegistryBeijing Chest Hospital NSCLC AI Prognostic Study – Prognosis prediction using multimodal models.Cleveland Clinic Pathomic PRA Study – Independent validation of AI-enabled prostate cancer risk assessment.Grandium Scanners – Compact desktop scanners for histology slides: Grandium.aiSupport the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors of the latest articles published in the Journal of Clinical Oncology. I'm your host, Dr. Davide Soldato, a medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by Dr. Lin, assistant professor in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Dr. Lin and I will be discussing the article titled, "Racial and Ethnic Disparities Along the Treatment Cascade Among  Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." Thank you for speaking with us, Dr. Lin. Dr. Lin: Thank you so much for having me. I appreciate it. Dr. Davide Soldato: So, just to start, to frame a little bit the study, I just wanted to ask you what prompted you and your team to look specifically at this question - so, racial and ethnic disparities within this specific population? And related to this question, I just wanted to ask how this work is different or builds on previous work that has been done on this research topic. Dr. Lin: Yeah, absolutely. Part of the impetus for this study was the observation that despite people who are black or Hispanic having equivalent health insurance status - they all have  Medicare Fee-for-Service - we've known that treatment and survival differences and disparities have persisted over time for patients with metastatic breast, colorectal, lung, and prostate cancer. And so, the question that we had was, "Why is this happening, and what can we do about it?" One of the reasons why eliminating racial and ethnic disparities in survival among Medicare beneficiaries with metastatic cancer has been elusive is because these disparities are occurring along a lot of dimensions. Whether or not it's because the patient presented late and has very extensive metastatic cancer; whether or not the patient has had a difficult time even seeing an oncologist; whether or not the patient has had a difficult time starting on any systemic therapy; or maybe it's because the patient has had a difficult time getting guideline-concordant systemic therapy because, more recently, these treatments have become so expensive. Disparities, we know, are occurring along all of these different facets and areas of the treatment cascade. Understanding which one of these is the most important is the key to helping us alleviate these disparities. And so, one of our goals was to evaluate disparities along the entire treatment cascade to try to identify which disparities are most important. Dr. Davide Soldato: Thank you very much. That was very clear. So, basically, one of the most important parts of the research that you have performed is really focusing on the entire treatment cascade. So, basically, starting from the moment of diagnosis up to the moment where there was the first line of treatment, if this line of treatment was given to the patient. So, I was wondering a little bit, because for this type of analysis, you used the SEER-Medicare linked database. So, can you tell us a little bit which was the period of time that you selected for the analysis? Why do you think that that was the most appropriate time to look at this specific question? And whether you feel like there is any potential limitation in using this type of database and how you handled this type of limitations? Dr. Lin: Yeah, absolutely. It's a great question. And I want to back up a little bit because I want to talk about the entire treatment cascade because I think that this is really important for our research and for future research. We weren't the first people to look at along the treatment cascade for a disease. Actually, this idea of looking along the treatment cascade was pioneered by HIV researchers and has been used for over a decade by people who study HIV. And there are a lot of parallels between HIV and cancer. One of them is that with HIV, there are so many areas along that entire treatment cascade that have to go right for somebody's treatment to go well. Patients have to be diagnosed early, they have to be given the right type of antiretrovirals, they have to be adherent to those antiretrovirals. And if you have a breakdown in any one of those areas, you're going to have disparities in care for these HIV patients. And so, HIV researchers have known this for a long time, and this has been a big cornerstone in the success of getting people with HIV the treatment that they need. And I think that this has a lot of parallels with cancer as well. And so, I am hoping that this study can serve as a model for future research to look along the entire treatment cascade for cancer because cancer is, similarly, one of these areas that requires multidisciplinary, complex medical care. And understanding where it is breaking down, I think, is crucial to us figuring out how we can reduce disparities. But for your question about the SEER-Medicare linked database, so we looked between 2016 and 2019. That was the most recent data that was available to us. And one of the reasons why we were excited to look at this is because there were some new treatments that were just released and FDA-approved around 2018, which we were able to study. And this included immunotherapy for non–small cell lung cancer, and then it also included androgen receptor pathway inhibitors, the second-generation ones, for prostate cancer. And the reason why this is important is because for some time, as we have developed these new therapies, there's been a lot of concern that there have been disparities in access to these novel therapies because of how expensive they are, particularly for the Medicare population. And so one of the reasons why we looked specifically at this time period was to understand whether or not, in more recent years, these novel therapies, people are having increasing disparities in them and whether or not increasing disparities in these more expensive, newer therapies is contributing to disparities in mortality. That being said, obviously, we're in 2025 and these data are by now six years old, and so there are additional therapies that are now available that weren't available in the past. But I think that, that being said, at least it's sort of a starting point for some of the more important therapies that have been introduced, at least for non–small cell lung cancer and prostate cancer. And the database, SEER-Medicare, is helpful because it uses the population cancer registry, which is the SEER registry cancer registry, linked to Medicare claims. So, any type of medical care that's billed through Medicare, which is going to basically be all of the medical care that these patients receive, for the most part, we're going to be able to see it. And so, I think that this is a really powerful database which has been used in a lot of research to understand what kind of care is being received that has been billed through Medicare. So, one of the limitations with this database is if there is care that's received that was not billed through Medicare, we're not going to be able to see that. And this does not happen probably that frequently, particularly because most patients who have insurance are going to be receiving care through insurance. However, we may see it for some of the oral Part D drugs. Some of those drugs are so expensive that patients cannot pay for the coinsurance during that time. And it's possible that some of those drugs patients were getting for free through the manufacturer. We potentially missed some of that. Dr. Davide Soldato: So, going a little bit into the results, I think that these are very, very interesting. And probably the most striking one is that when we look at the receipt of any type of treatment for metastatic breast, colorectal, prostate, and lung cancer - and specifically when we look at guideline-directed first-line treatments - you observed striking differences. So, I just wanted you to guide us a little bit through the results and tell us a little bit which of the numbers surprised you the most. Dr. Lin: So, what we were expecting is to see large disparities in receiving what we called guideline-directed systemic therapy. And guideline-directed systemic therapy during this time kind of depended on the cancer. So, we thought that we were going to see large disparities in guideline-directed therapy because these were the more novel therapies that were approved, and thus they were going to be the more expensive therapies. And so, what this meant was for colorectal cancer, this was going to be any 5-FU–based therapy. For lung cancer, this was going to be any checkpoint inhibitor–based therapy. For prostate cancer, this was going to be any ARPI, so this was going to be things like abiraterone or enzalutamide. And for breast cancer, this was going to be CDK4 and 6 TKIs plus any aromatase inhibitor. And so, for instance, for breast, prostate, and lung cancer, these were going to be including more expensive therapies. And so, what we expected to see was large disparities in receiving some of these more expensive, novel therapies. And we thought we were going to see fewer disparities in receiving some of the cheaper therapies, such as aromatase inhibitors, 5-FU, older platinum chemotherapies for lung cancer, and ADT for prostate cancer. We were shocked to find that we saw large racial and ethnic disparities in seeing some of the older, cheaper chemotherapies and hormonal therapies. So for instance, for breast cancer, 59% of black patients received systemic therapy, whereas 68% of white patients received systemic therapy. For colorectal, only 23% of black patients received any systemic therapy versus 34% of white patients. For lung, only 26% of black patients received any therapy, whereas 39% of white patients did. And for prostate, only 56% of black patients received any systemic therapy versus 77% of white patients. And so, we were pretty shocked by how large the disparities were in receiving these cheap, easy-to-access systemic therapies. Dr. Davide Soldato: Thank you very much. So, I just wanted to go a little bit deeper in the results because, as you said, there were striking differences even when we looked at very old and also cheap treatments that, for the majority of the patients that were included inside of your study, were actually basically available for a very small price to these patients who had the eligibility for Medicare or Medicaid. And I think that one of the very interesting parts of the research was actually the attention that you had at looking how much of these disparities could be explained by several factors. And actually, one of the most interesting results is that you observed that low-income subsidy status was actually a big determinant of these disparities in terms of treatment. So, I just wanted to guide us a little bit through these results and then just your opinion about how these results should be interpreted by policymakers. Dr. Lin: Yeah, absolutely. I'm going to explain a little bit about what low-income subsidy status is and dual-eligibility status. Some of the listeners may not know what low-income subsidy status or dual-eligibility status is. Low-income subsidy status is part of Medicare Part D. Medicare Part D is an insurance benefit that allows patients to receive oral drugs. So these are drugs that are dispensed through the pharmacy, such as the CDK4/6 inhibitors, as well as second-generation ARPIs in our study. For patients who have Medicare Part D and whose income is low enough - falls below a certain federal poverty level threshold - those patients will receive their oral drugs for much cheaper. And this is really important for some of these more novel therapies because for some of these more novel therapies, if you don't have low-income subsidy status, you may be paying thousands of dollars for a single prescription of those drugs. Whereas if you have low-income subsidy status, you may be paying less than $10. And so that difference, greater than $1,000 or $2,000 versus less than $10, one would think that the patient who's paying less than $10 would be much more likely to receive those therapies. So that's low-income subsidy status. Low-income subsidy status, importantly, doesn't apply for infused medications like immunotherapy. But it's important to know that most people with low-income subsidy status - about 88% - are also dual-eligible. What dual-eligible means is that they have both Medicare and Medicaid. Medicare being the insurance that everybody has in our study who's greater than 65. And Medicaid is the state-run but federally subsidized insurance that patients with low incomes have. And so patients who are dual-eligible - and about 87% of those with low-income subsidy status are dual-eligible - those patients have both Medicaid and Medicare, and they basically pay next to nothing for any of their medical care. And that's because Medicare will reimburse most of the medical care and the copays or coinsurance are going to be covered by Medicaid. So Medicaid is going to pick up the rest of the bill. So, most of the patients who have low-income subsidy status who are dual-eligible, these patients pay almost nothing for their medical care - Part B or Part D, any of their drugs. And so, one would expect that if cost were the main determinant of disparities in cancer care, then one would expect that dual-eligibles, most of them would be receiving treatment because they're facing minimal to no costs. What we found is that when we broke down the racial and ethnic disparity by a number of factors - including LIS status/dual eligibility, age, the number of comorbidities, etcetera - what we found was that the LIS or dual-eligibility status explained about 20% to 45% of the disparities that we saw in receiving treatment. And what that means is despite these patients paying next to nothing for their drugs, these are the most likely patients to not be treated for their cancer at all. So they're most likely to basically be diagnosed, survive for two months, see an oncologist, and then never receive any systemic therapy for their cancer. And this is not just chemotherapies for colorectal or lung cancer. This includes cheaper, easier-to-tolerate hormonal therapies that you can just take at home for breast cancer, or you can get every six months for prostate cancer, that people who even have poorer functional status are able to take. However, for whatever reason, these dual-eligible or LIS patients are very unlikely to receive treatment compared to any other patient. The low likelihood of treating this group of patients, that explains a large portion of the racial and ethnic disparities that we see. Dr. Davide Soldato: And one thing that I think is very interesting and might be of potential interest to our listeners is, did you compare survival outcomes in these different settings? And did you observe any significant differences in terms of racial and ethnic disparities once you saw that there was a significant difference when looking at both receipt of any type of treatment and also guideline-directed treatments? Dr. Lin: We saw that there were large disparities in survival by race and ethnicity when you look overall. However, when you just account for the patients who received any systemic therapy at all - not just guideline-directed systemic therapy - those differences in survival essentially disappeared. And so, what that suggests is that if black patients were just as likely to receive any systemic therapy at all as white patients, we would expect that the survival differences that we were seeing would disappear. And this is not even just looking at guideline-directed systemic therapy. This was looking just at systemic therapy alone. And so, while guideline-directed systemic therapy should be a goal, our research suggests that if we are to close the gap in disparities in overall survival among black and white patients, we must first focus on patients just receiving any type of treatment at all. And that should be the very first focus that policymakers, that leaders in ASCO, that health system leaders, that physicians, that we should focus on: just trying to get any type of treatment to our patients who are poorer or black. Dr. Davide Soldato: Thank you very much. And this was not directly related to the research that you performed, but going back to this very point - so, increasing the number of patients that receive any kind of systemic treatment before looking at guideline-directed treatments - what would you feel would be the best way to approach this in order to decrease the disparities? Would you look at interventions such as financial navigation or maybe improving referral pathways or providing maybe more culturally adapted information to the patients? Because in the end, what we see is disparities based on racial and ethnicity. We see that we can reduce these disparities if we get these patients to the treatment. But in the end, what would you feel is the best way to bring patients to these types of treatments? Dr. Lin: I think the most important thing is to understand that these disparities are not primarily happening because of the high cost of cancer treatment. These disparities are happening because of other social vulnerabilities that these patients are facing. And so these vulnerabilities could be a lot of things. It could be mistrust of the medical system. It could be fear of chemotherapy or other treatments. It could be difficulty taking time off of work. It could be any number of things. What we do know is when we've looked at the types of interventions that can help patients receive treatment, navigation is probably the most effective one. And the reason why I think that is because when patients don't receive treatment because of social vulnerability, I sort of look at social vulnerability like links in a chain. Any weakest link is going to result in the patient not receiving treatment. This may be because they have a hard time taking time off of work. This may be because they had a hard time getting transportation to their physician. It may be because they had an interaction with a physician, but that interaction was challenging for the patient. Maybe they mistrusted the physician. Maybe they're worried about the medical system. If any of these things goes wrong, the patient is not going to be treated. The patient navigator is the only person who can spot any of those weak links within the chain and address them. And so, I think that the first thing to do is to get patient navigation systems in place for our vulnerable patients throughout the United States. And this is incredibly important because in Medicare, patient navigation is reimbursable. And so this is not something that's ‘pie in the sky'. This is something that's achievable today. The second thing is that it's really important that we see these vulnerabilities happening for patients who are dual-eligible, who have both Medicare and Medicaid. One of the reasons why this is important is because there has been a lot of research outside of what we've done that has shown vulnerabilities for dual-eligible patients who have Medicare for a number of different diseases. And the reason why is because, although patients are supposed to have the benefits of both Medicare and Medicaid, usually these two insurances do not play nicely together. It creates a huge, bureaucratic, complex mess and maze that most of these patients are unable to navigate. And so many of these patients are unable to actually receive the full reimbursement from both Medicare and Medicaid that they should be getting because those two insurers are not communicating well. And so the second thing is that national cancer organizations need to be supporting policies and legislation that is already being discussed in Congress to revamp the dual-eligible system so that it facilitates these patients getting properly reimbursed for their care from both Medicare and Medicaid and these systems working together well. The third thing is that Medicaid itself has many benefits that can allow patients to receive care, like they have transportation benefits so that patients can get to and from their doctor's appointments with ease. And so I think this will be additionally very, very helpful for patients. The last thing is, you know, it's possible that future innovations such as telemedicine and tele-oncology and cancer care at home can also make it easier for some of these patients who may be working a lot to receive care. But what I would say is that our study should be a call for healthcare delivery researchers to start piloting interventions to be able to help these patients receive systemic therapy. And so what this could look like is trying to get that care navigation and implement that in clinics so that patients can be receiving the care that they need. Dr. Davide Soldato: Thank you very much. That was a very clear perspective on how we can tackle this issue. So, I just wanted to close with a sort of personal question. I was wondering what led you to work specifically in this research field that is very challenging, but I think it's particularly critical in healthcare systems like in the United States. Dr. Lin: Yeah, absolutely. One of the most important things for me as an oncologist and a researcher is being able to know that all patients in the United States - and obviously abroad - who have cancer should be able to receive the kind of care that they deserve. I don't think that patients, because their incomes are lower or because their skin looks a certain color or because they live in rural areas, these shouldn't be determinants of whether or not cancer patients are receiving the care that they need. We can develop and pioneer the very best treatments and breakthroughs in oncology, but if our patients are not receiving them - if only 20% of our patients with colon cancer or lung cancer are receiving any type of systemic therapy, who are black - this is a big problem. But this is something that I think that our system can tackle. We need to get these breakthroughs that we have in oncology to every single cancer patient in America and every single cancer patient in the world. I think this is a goal that all oncologists should have, and I think that this is something that, honestly, is achievable. I think that research is a powerful tool to give us a lens into understanding exactly why it is that certain patients are not getting the care that they deserve. And my goal is to continue to use research to shed light on why our system is not performing the way that we all want it to be. Dr. Davide Soldato: Circling back to your research, actually the manuscript that was published was supported by a Young Investigator Award by the American Society of Clinical Oncology. So, was this the first step of a more broad research, or do you have any further plans to go deeper in this topic? Dr. Lin: Yeah, absolutely. First, I want to thank the ASCO Young Investigator Award for funding this research because I think it's fair to say that this research would not have happened at all without the support of the ASCO YIA. And the fact that ASCO is doing as much as it can to support the future generation of cancer researchers is incredible. And it's a huge resource, and having it come at the time that it did is critical for so many of us. So I think that this is an unbelievable thing that ASCO does and continues to do with all of its partners. For me, yeah, this is definitely a stepping stone to further research.  Medicare Fee-for-Service is only one part of the population. I want to spread this research and extend it to patients who have other types of insurances, look at other types of policies, and also try to conduct some of the cancer care delivery research that's needed to try to pilot some interventions that can resolve this problem. So hopefully this is the first step in a broader series of studies that we can all do collectively to try to eliminate racial and ethnic disparities in cancer care and survival. Dr. Davide Soldato: So, I think that we've come at the end of this podcast. Thank you again, Dr. Lin, for joining us today. Dr. Lin: Thank you so much. It was a pleasure to be a part of this. Dr. Davide Soldato: So, we appreciate you sharing more on your JCO article, "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

This week, Dr. Joel Kahn reviews the latest research on men's health, focusing on diet and prostate cancer. He highlights findings that support whole-food, plant-based diets and discusses the connection between prostate cancer, heart disease, and the cardiovascular risks associated with androgen deprivation therapy (ADT). Other topics covered include plant-based diets and disease rates, the role of LDL cholesterol in soft plaque formation, TMAO in abdominal aortic aneurysms and kidney disease, periodontal disease and its impact on heart health, saccharin and cardiovascular risk, extreme physical activity and carotid plaque, and the effects of Tylenol use during pregnancy.  Dr. Kahn also reviews new research on cyclodextrin suppositories, a paper examining the impact of statins on blood sugar, and the potential role of TUDCA as a possible antidote.  Resources mentioned in this episode include the cyclodextrin paper available at www.atherocare.com/drjoelkahn and details on TUDCA at https://shop.drjoelkahn.com/catalog/product/view/id/17560/s/tudca-tauroursodeoxycholic-acid-60-capsules/. Special thanks to our sponsor Igennus.com, use discount code DrKahn for all products.

Aiden Deacon from the University of Minnesota-Twin Cities, Minneapolis, discusses a research paper he co-authored that was published in Volume 16 of Oncotarget, titled “Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer.” DOI - https://doi.org/10.18632/oncotarget.28758 Correspondence to - Justin Hwang - jhwang@umn.edu Video interview - https://www.youtube.com/watch?v=OXKhWWU1gnY Abstract This study investigates the R-spondin family of genes (RSPO1/2/3/4), a group of secreted proteins that act as Wnt regulators, and their subsequent role in advanced prostate cancer (PC). When evaluating transcriptomic data from primary and metastatic PC patients, we found that alterations in RSPO2 were more prevalent than in other RSPO family members or Wnt-regulating genes APC and CTNNB1. Further, we found that RSPO2 alterations in PCs were significantly associated with worse disease-free survival. Through our in silico modeling, RSPO2 exhibited strong positive associations with genes regulating epithelial-mesenchymal transition (EMT) and double-negative prostate cancer (DNPC), but had negative correlations with androgen receptor (AR) and AR-associated genes. Furthermore, 3D modeling of RSPO2 revealed structural differences between itself and other RSPOs. In cell lines, RSPO2 overexpression caused up-regulation of EMT pathways, including EMT-regulatory transcription factors ZEB1, ZEB2, and TWIST1. Conversely, this was not observed when CTNNB1 was overexpressed in the same models. These findings highlight that, in PC, RSPO2 functions as a unique member of the R-spondin family by promoting genes and signaling pathways associated with aggressive PC, and RSPO2 amplifications are associated with poor outcomes in PC patients. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28758 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, RSPO2, prostate cancer, Wnt signaling, genomics, therapeutics About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

A plant-based lifestyle is put to the test against early and late-stage cancer

The “China Study” is cited as evidence vegetarian diet is best—but big new study shows vegetarians age less well than omnivores; Can a popular men's health supplement ward off prostate cancer? MAHA officials hit pause on looming natural thyroid ban; Can diet alleviate symptoms of lipedema? Precision-engineering your gait can alleviate knee pain better than NSAIDs; After a lifetime of profound depression, novel brain implant enables man to experience joy for the first time.

In this deeply moving episode, Rick sits down with poet and cancer survivor Mickie Kennedy to explore how poetry became a tool for healing after prostate and colon cancer. Together, they unpack the power of storytelling, the challenges of queer survival during the AIDS crisis, and the urgency of preserving LGBTQ+ histories. From laughter about fiducials to tearful reflections on family and legacy, this episode invites you to witness resilience, creativity, and the choice to keep living out loud. In this episode you'll Learn how to heal through creative expression Discover ways you can give yourself permission to feel, create, and heal Understand why Queer stories matter and how they can support your own challenging journeys About Mickie Mickie Kennedy is a gay writer who resides in Baltimore County, Maryland. His work has appeared in POETRY, The Threepenny Review, The Southern Review, The Sun and elsewhere. His chapbook Glandscapes, published by Button Poetry, can be ordered at Glandscapes.com. Connect With Mickie Website Instagram Facebook LinkedIn

Join me, Suzanne Noble, as I chat with the brilliant Dr. Pete Tsambarlis, an associate professor of urology at Northwestern University, who knows more about prostates than most of us know about our morning coffee! Dr. Tsambarlis was introduced to me by a patient of his, fellow Substacker Bob Mizek-Menopause for men, so I knew we were going to have a fascinating conversation around importance of understanding prostate cancer, the effects of treatment on erectile function, and the recovery timeline after surgery. Dr. Tsambarlis emphasised the role of medications, lifestyle changes, and the significance of having a supportive healthcare team. The conversation also touches on Peyronie's disease and the importance of proactive health management for better sexual outcomes.Listen as Dr. Tsambarlis shares his wisdom on everything from avoiding the dreaded prostate cancer to why your heart health is your best friend below the belt plus tips on how to have those awkward conversations with your doctor without embarrassment or shame.00:00 Introduction to Sexual Health and Prostate Cancer01:56 Understanding Prostate Cancer and Prevention04:02 Supporting Men Through Prostate Treatment09:46 Recovery After Prostate Surgery10:56 The Role of Medications in Erectile Function14:18 Empowering Patients: Questions to Ask Your Doctor16:49 Exploring Peyronie's Disease22:32 Taking Control of Sexual Health28:06 Building a Supportive Healthcare TeamWhat's this about?Hi, I'm Suzanne, author of the bestseller ‘The Butcher, the Baker, the Candlestick Maker: An Erotic Memoir,' pleasure seeker and curious about ways to improve our intimate relationships as we age.Each week, I delve into a different aspects of sex, dating and relationships with an expert which I bring to you via the Sex Advice for Seniors podcast. Once a week, I write or invite a guest to write a more personal story, which could be in the form of an erotic experience, a sex toy review or perhaps a new perspective, typically behind a paywall.Alongside this Substack, I advocate for the right to sexual pleasure in later life through speaking engagements, attending conferences and other events, which your subscription helps to pay me to attend.Being a subscriber has multiple benefits for you:* Receive my book, ‘Sex Toys & Supplements for Thriving in Later Life' * Join my private chat where you can ask questions of a personal nature* Helping to contribute to the conversation around sex and sexual health in later lifeI'm grateful for each and every subscriber that pays £6.99 or £49.99 per year so do consider taking a subscription if you have the means to do so.Hey, but don't take it from me. Here's what others say about Sex Advice for Seniors:“Not enough older voices talking about sex. Are we just supposed to dry up and fade away?”“I enjoy staying abreast of new ideas and learning new ways to please my wife.”“Straight non judgmental information that relates to my needs.” Get full access to Sex Advice for Seniors at www.sexadviceforseniors.com/subscribe

Radiation oncologist Dr. Julian Hong explains how radiation therapy works and its central role in treating prostate cancer, both when the disease is localized and when it has spread to limited areas. He outlines major radiation options, including external beam radiation, stereotactic body radiation therapy (SBRT), and brachytherapy, and describes how treatment plans are carefully tailored using imaging, planning scans, and computer modeling to maximize precision and minimize side effects. Hong highlights advances in targeting and beam modulation, which allow for safer, more effective treatment. He also discusses typical timelines for treatment, short- and long-term side effects, and the importance of ongoing follow-up to manage late effects of therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40803]

Radiation oncologist Dr. Julian Hong explains how radiation therapy works and its central role in treating prostate cancer, both when the disease is localized and when it has spread to limited areas. He outlines major radiation options, including external beam radiation, stereotactic body radiation therapy (SBRT), and brachytherapy, and describes how treatment plans are carefully tailored using imaging, planning scans, and computer modeling to maximize precision and minimize side effects. Hong highlights advances in targeting and beam modulation, which allow for safer, more effective treatment. He also discusses typical timelines for treatment, short- and long-term side effects, and the importance of ongoing follow-up to manage late effects of therapy. Series: "Prostate Cancer Patient Conference" [Health and Medicine] [Show ID: 40803]

Preventing and Treating Erectile Dysfunction (ED) In the 2nd half of this episode learn about dietary factors, including the exclusion of meat, dairy and eggs, that can help you live without pain from arthritis. Written by Thomas Campbell, MD at the T. Colin Campbell Center for Nutrition Studies. #vegan #plantbased #veganpodcast #plantbasedpodcast #plantbasedbriefing #ed #erectiledysfunction #heartdisease   ======================== Original post: https://nutritionstudies.org/preventing-and-treating-erectile-dysfunction-e-d/  ========================== Related Episodes: 1106, 1064/5, 755, 602, 583/4, 494, 473, 148 1106: From Bacon-Lover to Vegan: My Unlikely Journey to Better Health https://plantbasedbriefing.libsyn.com/1106-from-bacon-lover-to-vegan-my-unlikely-journey-to-better-health-by-craig-milton-at-forksoverknivescom  1064: [Part 1] Diet, Lifestyle And Prostate Cancer by Dr. Shireen Kassam https://plantbasedbriefing.libsyn.com/1064-part-1-diet-lifestyle-and-prostate-cancer-by-dr-shireen-kassam-at-plantbasedhealthprofessionalscom  1065: [Part 2] Diet, Lifestyle And Prostate Cancer https://plantbasedbriefing.libsyn.com/1065-part-2-diet-lifestyle-and-prostate-cancer-by-dr-shireen-kassam-at-plantbasedhealthprofessionalscom 755: New Study: Plant-Based Foods Could Improve Men's Sexual Health After Prostate Cancer Treatment https://plantbasedbriefing.libsyn.com/743-new-study-plant-based-foods-could-improve-mens-sexual-health-after-prostate-cancer-treatment-by-charlotte-pointing-at-vegnewscom 602: How Erectile Dysfunction Can Save a Life (and Be Reversed) https://plantbasedbriefing.libsyn.com/602-how-erectile-dysfunction-can-save-a-life-and-be-reversed-by-joel-kahn-md-at-forksoverknivescom 584: [Part 2] What Is Cholesterol? How It Works, Foods to Avoid, and the Truth About HDL https://plantbasedbriefing.libsyn.com/584-part-2-what-is-cholesterol-how-it-works-foods-to-avoid-and-the-truth-about-hdl-by-courtney-davison-at-forksoverknivescom 494: Milk Drinkers See 60% Higher Rates of Prostate Cancer https://plantbasedbriefing.libsyn.com/494-milk-drinkers-see-60-higher-rates-of-prostate-cancer-by-meghan-edwards-at-forksoverknivescom 473: Lower Rates of Erectile Dysfunction Linked to Plant-Based Diets https://plantbasedbriefing.libsyn.com/473-lower-rates-of-erectile-dysfunction-linked-to-plant-based-diets-by-megan-edwards-at-forksoverknivescom 148: Fight Erectile Dysfunction and 4 More Reasons to Go Plant Based This Movember https://plantbasedbriefing.libsyn.com/148-fight-erectile-dysfunction-and-4-more-reasons-to-go-plant-based-this-movember-by-josh-cullimore-md-at-pcrmorg   use search feature at https://www.plantbasedbriefing.com/episodes-search      ========================= The T. Colin Campbell Center for Nutrition Studies was established to extend the impact of Dr. Campbell's life changing research findings. For decades, T. Colin Campbell, PhD, has been at the forefront of nutrition education and research. He is the coauthor of the bestselling book, The China Study, and his legacy, the China Project, is one of the most comprehensive studies of health and nutrition ever conducted. Their mission is to promote optimal nutrition through science-based education, advocacy, and research. By empowering individuals and health professionals, we aim to improve personal, public, and environmental health. ====================== FOLLOW THE SHOW ON: YouTube: https://www.youtube.com/@plantbasedbriefing     Spotify: https://open.spotify.com/show/2GONW0q2EDJMzqhuwuxdCF?si=2a20c247461d4ad7 Apple Podcasts: https://podcasts.apple.com/us/podcast/plant-based-briefing/id1562925866 Your podcast app of choice: https://pod.link/1562925866 Facebook: https://www.facebook.com/PlantBasedBriefing   LinkedIn: https://www.linkedin.com/company/plant-based-briefing/ 

Charity Prostate Cancer UK says some people are being treated when they don't need to be. Learn about this news story with Phil and Pippa.Find full subtitles and a worksheet for this episode at: https://www.bbc.co.uk/learningenglish/english/features/learning-english-from-the-news_2025/250813FIND BBC LEARNING ENGLISH HERE: Visit our website ✔️ https://www.bbc.co.uk/learningenglish Follow us ✔️ https://www.bbc.co.uk/learningenglish/followusSUBSCRIBE TO OUR NEWSLETTER: ✔️ https://www.bbc.co.uk/learningenglish/newslettersFor more of our podcasts, search for these in your podcast app: ✔️ Learning English for Work ✔️ Learning Easy English ✔️ Learning English Grammar ✔️ Learning English Stories ✔️ 6 Minute English ✔️ Learning English Conversations ✔️ Learning English Vocabulary

BUFFALO, NY – August 11, 2025 – A new #researchpaper was #published in Volume 16 of Oncotarget on July 25, 2025, titled “Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer.” In this study, researchers led by first author Aiden Deacon and corresponding author Justin Hwang from the University of Minnesota-Twin Cities investigated a group of genes known as the R-spondin family (RSPO1/2/3/4) in advanced prostate cancer (PC). The RSPO gene family regulates Wnt signaling, a pathway involved in cancer progression. Prostate cancer is the most common cancer among men in the United States and becomes especially dangerous when it spreads beyond the prostate. Most patients are treated with hormone therapies that target the androgen receptor; however, many tumors eventually become resistant. The research team analyzed thousands of tumor samples and found that RSPO2 alterations were more common than changes in other R-spondin genes or even some well-known cancer-related genes like CTNNB1 and APC. RSPO2 amplification occurred in over 20% of metastatic prostate cancer. Patients with these alterations showed signs of more aggressive disease, including higher mutation rates and greater tumor complexity. Using laboratory models, the team discovered that RSPO2 increases cancer cell growth and triggers a biological process called epithelial-mesenchymal transition (EMT). EMT is known to promote tumor spread and resistance to standard treatments. Unlike other genes in the same pathway, RSPO2 also appeared to reduce the activity of androgen receptor genes, suggesting it drives a type of prostate cancer that no longer relies on hormones for growth. “In cell lines, RSPO2 overexpression caused up-regulation of EMT pathways, including EMT-regulatory transcription factors ZEB1, ZEB2, and TWIST1.” Importantly, RSPO2 showed structural differences from other R-spondin proteins, which may allow researchers to design drugs that specifically block its activity. Current therapies targeting the Wnt pathway are limited, and there are no approved drugs that inhibit RSPO2. However, this study highlights RSPO2 as a promising therapeutic target, especially for patients who do not respond to existing hormone-based treatments. This research adds critical knowledge about how aggressive prostate cancers develop and persist despite therapy. The identification of RSPO2 as a key driver of disease progression opens new possibilities for treatment strategies aimed at improving outcomes for patients with advanced prostate cancer. DOI - https://doi.org/10.18632/oncotarget.28758 Correspondence to - Justin Hwang - jhwang@umn.edu Video short - https://www.youtube.com/watch?v=iyu5D_c1dbY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28758 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, RSPO2, prostate cancer, Wnt signaling, genomics, therapeutics To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Holly Cotton (breast cancer survivor, nurse, author) and Dewayne Charleston (stage 4 prostate cancer survivor). Topic: Raising awareness and eliminating disparities in Black men’s health, especially prostate cancer. 2. Holly Cotton’s Story Breast cancer survivor and nurse with a master’s degree. Author of Strong More Than Muscles. Uses her survivorship to inspire others and promote health awareness. Advocates for being a “life survivor,” not just a cancer survivor. 3. Rushion McDonald’s Personal Experience Thyroid cancer survivor since 2015. Shares how the diagnosis changed his perspective on life and purpose. Uses his platform to raise awareness and encourage proactive health decisions. 4. Dwayne’s Journey Diagnosed with stage 4 prostate cancer at age 46. All 16 biopsy samples came back positive. Told by MD Anderson urologist Dr. Lewis Sisler that only prayer could help. Fought cancer for 14 years and founded a prostate cancer awareness foundation. 5. Foundation Mission Educates Black men on prostate cancer, clinical trials, and health disparities. Addresses emotional, sexual, financial, and relational impacts of cancer. Aims to break silence and stigma around men’s health issues. 6. Breast Cancer Awareness vs. Prostate Cancer Awareness Holly explains the success of “Go Pink” campaigns for breast cancer. Dewayne and Holly aim to replicate that success with “Go Blue” for prostate cancer. Goal: Encourage men to prioritize their own health and get tested. 7. Community Impact Importance of storytelling and visibility at events like HBCU games. Emphasis on legacy, education, and proactive health care. Holly and Dewayne’s collaboration bridges gender and cancer awareness gaps. 8. Closing Rushon thanks guests for their advocacy and friendship. Encourages listeners to lead with their gifts and keep winning.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Holly Cotton (breast cancer survivor, nurse, author) and Dewayne Charleston (stage 4 prostate cancer survivor). Topic: Raising awareness and eliminating disparities in Black men’s health, especially prostate cancer. 2. Holly Cotton’s Story Breast cancer survivor and nurse with a master’s degree. Author of Strong More Than Muscles. Uses her survivorship to inspire others and promote health awareness. Advocates for being a “life survivor,” not just a cancer survivor. 3. Rushion McDonald’s Personal Experience Thyroid cancer survivor since 2015. Shares how the diagnosis changed his perspective on life and purpose. Uses his platform to raise awareness and encourage proactive health decisions. 4. Dwayne’s Journey Diagnosed with stage 4 prostate cancer at age 46. All 16 biopsy samples came back positive. Told by MD Anderson urologist Dr. Lewis Sisler that only prayer could help. Fought cancer for 14 years and founded a prostate cancer awareness foundation. 5. Foundation Mission Educates Black men on prostate cancer, clinical trials, and health disparities. Addresses emotional, sexual, financial, and relational impacts of cancer. Aims to break silence and stigma around men’s health issues. 6. Breast Cancer Awareness vs. Prostate Cancer Awareness Holly explains the success of “Go Pink” campaigns for breast cancer. Dewayne and Holly aim to replicate that success with “Go Blue” for prostate cancer. Goal: Encourage men to prioritize their own health and get tested. 7. Community Impact Importance of storytelling and visibility at events like HBCU games. Emphasis on legacy, education, and proactive health care. Holly and Dewayne’s collaboration bridges gender and cancer awareness gaps. 8. Closing Rushon thanks guests for their advocacy and friendship. Encourages listeners to lead with their gifts and keep winning.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Holly Cotton (breast cancer survivor, nurse, author) and Dewayne Charleston (stage 4 prostate cancer survivor). Topic: Raising awareness and eliminating disparities in Black men’s health, especially prostate cancer. 2. Holly Cotton’s Story Breast cancer survivor and nurse with a master’s degree. Author of Strong More Than Muscles. Uses her survivorship to inspire others and promote health awareness. Advocates for being a “life survivor,” not just a cancer survivor. 3. Rushion McDonald’s Personal Experience Thyroid cancer survivor since 2015. Shares how the diagnosis changed his perspective on life and purpose. Uses his platform to raise awareness and encourage proactive health decisions. 4. Dwayne’s Journey Diagnosed with stage 4 prostate cancer at age 46. All 16 biopsy samples came back positive. Told by MD Anderson urologist Dr. Lewis Sisler that only prayer could help. Fought cancer for 14 years and founded a prostate cancer awareness foundation. 5. Foundation Mission Educates Black men on prostate cancer, clinical trials, and health disparities. Addresses emotional, sexual, financial, and relational impacts of cancer. Aims to break silence and stigma around men’s health issues. 6. Breast Cancer Awareness vs. Prostate Cancer Awareness Holly explains the success of “Go Pink” campaigns for breast cancer. Dewayne and Holly aim to replicate that success with “Go Blue” for prostate cancer. Goal: Encourage men to prioritize their own health and get tested. 7. Community Impact Importance of storytelling and visibility at events like HBCU games. Emphasis on legacy, education, and proactive health care. Holly and Dewayne’s collaboration bridges gender and cancer awareness gaps. 8. Closing Rushon thanks guests for their advocacy and friendship. Encourages listeners to lead with their gifts and keep winning.

Sweet poison? New doubts cast over safety of erythritol; Is Greek yogurt a good way to enhance protein intake? Comparing whey, soy, and pea protein isolates; When taking supplements, is it advisable to take periodic breaks to enhance their effectiveness? Tommy John surgery pioneer and longtime Mets medical director dies at 68; Ivermectin, once branded useless “horse paste,” may prove a new weapon against malaria; New findings challenge notion that humans and apes share 99% of their DNA.

In this episode, our guest, Dr. Andrew Armstrong of Duke University, discusses recent advances that men should know to overcome prostate cancer. We ask about former President Joe Biden's diagnosis. What does it mean to have Stage IV prostate cancer and a Gleason score of 9? News outlets have reported that Mr. Biden's previous prostate […]